α-Gal-Based Vaccines: Advances, Opportunities, and Perspectives

Trends Parasitol. 2020 Dec;36(12):992-1001. doi: 10.1016/j.pt.2020.08.001. Epub 2020 Sep 15.

Abstract

Humans and crown catarrhines evolved with the inability to synthesize the oligosaccharide galactose-α-1,3-galactose (α-Gal). In turn, they naturally produce high quantities of the glycan-specific antibodies that can be protective against infectious agents exhibiting the same carbohydrate modification on their surface coat. The protective immunity induced by α-Gal is ensured through an antibody-mediated adaptive and cell-mediated innate immune response. Therefore, the α-Gal antigen represents an attractive and feasible target for developing glycan-based vaccines against multiple diseases. In this review article we provide an insight into our current understanding of the mechanisms involved in the protective immunity to α-Gal and discuss the possibilities and challenges in developing a single-antigen pan-vaccine for prevention and control of parasitic diseases of medical and veterinary concern.

Keywords: immunity; immunization; parasites; protection; vaccine; α-Gal.

Publication types

  • Review

MeSH terms

  • Adaptive Immunity / immunology
  • Animals
  • Antibodies / immunology*
  • Humans
  • Parasitic Diseases / immunology*
  • Parasitic Diseases / prevention & control*
  • Vaccines / immunology*

Substances

  • Antibodies
  • Vaccines